(VIANEWS) – Flaherty & Crumrine (FFC), Lexington Realty Trust (LXP), BP (BP) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| Flaherty & Crumrine (FFC) | 8.21% | 2023-05-02 14:23:07 |
| Lexington Realty Trust (LXP) | 5.37% | 2023-05-03 19:09:07 |
| BP (BP) | 3.59% | 2023-05-03 10:38:48 |
| Bristol (BMY) | 3.24% | 2023-05-03 14:34:14 |
| Phibro Animal Health Corporation (PAHC) | 3.02% | 2023-04-22 19:43:07 |
A little less 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Flaherty & Crumrine (FFC) – Dividend Yield: 8.21%
Flaherty & Crumrine’s last close was $13.94, 24.61% below its 52-week high of $18.49. Intraday change was -2.44%.
Flaherty & Crumrine Preferred Securities Income Fund Inc. is a closed-ended balanced mutual fund launched and managed by Flaherty & Crumrine Incorporated. The fund invests in the public equity and fixed income markets of the United States. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in investment grade preferred securities consisting of hybrid or taxable preferreds. It employs quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Merrill Lynch 8% Capped DRD Preferred Stock Index, Merrill Lynch Hybrid Preferred Securities Index, and Merrill Lynch Adjustable Preferred Stock 7% Constrained Index. It was formerly known as Flaherty & Crumrine/Claymore Preferred Securities Income Fund Incorporated. Flaherty & Crumrine Preferred Securities Income Fund Inc. was formed on May 23, 2002 and is domiciled in the United States.
Earnings Per Share
As for profitability, Flaherty & Crumrine has a trailing twelve months EPS of $-3.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.62%.
Volatility
Flaherty & Crumrine’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.04%, a negative 0.03%, and a positive 1.36%.
Flaherty & Crumrine’s highest amplitude of average volatility was 0.90% (last week), 0.88% (last month), and 1.36% (last quarter).
More news about Flaherty & Crumrine.
2. Lexington Realty Trust (LXP) – Dividend Yield: 5.37%
Lexington Realty Trust’s last close was $9.65, 23.47% under its 52-week high of $12.61. Intraday change was 3.65%.
Lexington Realty Trust (NYSE: LXP) is a publicly traded real estate investment trust (REIT) that owns a diversified portfolio of real estate assets consisting primarily of equity investments in single-tenant net-leased commercial properties across the United States. Lexington seeks to expand its industrial portfolio through build-to-suit transactions, sale-leaseback transactions and other transactions, including acquisitions.
Earnings Per Share
As for profitability, Lexington Realty Trust has a trailing twelve months EPS of $0.38.
PE Ratio
Lexington Realty Trust has a trailing twelve months price to earnings ratio of 25.39. Meaning, the purchaser of the share is investing $25.39 for every dollar of annual earnings.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 5.37%.
Volume
Today’s last reported volume for Lexington Realty Trust is 3229820 which is 54.86% above its average volume of 2085600.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Lexington Realty Trust’s EBITDA is 82.64.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lexington Realty Trust’s stock is considered to be oversold (<=20).
More news about Lexington Realty Trust.
3. BP (BP) – Dividend Yield: 3.59%
BP’s last close was $36.46, 11.89% under its 52-week high of $41.38. Intraday change was -0.5%.
BP p.l.c. provides carbon products and services. The company operates through Gas & Low Carbon Energy, Oil Production & Operations, and Customers & Products segments. It engages in the production of natural gas, and integrated gas and power; trading of gas; operation of onshore and offshore wind power, as well as hydrogen and carbon capture and storage facilities; trading and marketing of renewable and non-renewable power; and production of crude oil. In addition, the company involved in convenience and retail fuel, EV charging, Castrol lubricant, aviation, B2B, and midstream businesses; refining and oil trading; and bioenergy business. Further, it engages in power and storage, digital transformation, carbon management, and bio and low carbon related products, as well as energy and environmental commodities and mobility businesses. The company was founded in 1908 and is headquartered in London, the United Kingdom.
Earnings Per Share
As for profitability, BP has a trailing twelve months EPS of $-0.78.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.57%.
Previous days news about BP
- : European stocks trade mixed after three-day break; HSBC shares rallies while BP fizzles. According to MarketWatch on Tuesday, 2 May, "HSBC Holdings shares UK:HSBA jumped 5% after reporting a big profit surge in the first quarter, while BP UK:BP slipped 5% even as its results topped earnings expectations. "
- BP share price slips on cautious outlook. According to FXStreet on Tuesday, 2 May, "Last month BP reinforced that by bringing a new platform, Mad Dog Phase 2, online in the Gulf of Mexico, while saying it plans to continue to boost oil and gas production capacity further.", "The wider question is how BP defines its "transition growth engines" given that LNG could easily be described as a transition energy source, given it is cleaner than coal and oil."
More news about BP.
4. Bristol (BMY) – Dividend Yield: 3.24%
Bristol’s last close was $66.64, 18.17% below its 52-week high of $81.44. Intraday change was -2.29%.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.41.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 19.51. Meaning, the purchaser of the share is investing $19.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.91%.
Yearly Top and Bottom Value
Bristol’s stock is valued at $66.54 at 10:15 EST, way below its 52-week high of $81.44 and higher than its 52-week low of $65.28.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 5, 2023, the estimated forward annual dividend rate is 2.28 and the estimated forward annual dividend yield is 3.24%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1.5% and 7.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.8%, now sitting on 46.16B for the twelve trailing months.
More news about Bristol.
5. Phibro Animal Health Corporation (PAHC) – Dividend Yield: 3.02%
Phibro Animal Health Corporation’s last close was $15.89, 22.64% under its 52-week high of $20.54. Intraday change was 1.79%.
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Earnings Per Share
As for profitability, Phibro Animal Health Corporation has a trailing twelve months EPS of $0.89.
PE Ratio
Phibro Animal Health Corporation has a trailing twelve months price to earnings ratio of 17.85. Meaning, the purchaser of the share is investing $17.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.28%.
Moving Average
Phibro Animal Health Corporation’s value is higher than its 50-day moving average of $15.45 and above its 200-day moving average of $15.26.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 972.05M for the twelve trailing months.
Sales Growth
Phibro Animal Health Corporation’s sales growth is 3.3% for the current quarter and 1.6% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Phibro Animal Health Corporation’s EBITDA is 38.31.
More news about Phibro Animal Health Corporation.
